Journal Article

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer

Fujii, Satoshi, Yamaguchi, Kensei, Fujitani, Kazumasa, Shitara, Kohei, Baba, Eishi, Oki, Eiji

2021

Overview

Approximately 12–15% of gastric cancers (GCs) are human epidermal growth factor receptor-2 (HER2)-positive (HER2 immunohistochemistry 3 + or 2 + /in situ hybridization + [ERBB2/CEP17 ≥ 2.0]). While the anti-HER2 monoclonal antibody trastuzumab, in combination with chemotherapy, is the standard treatment for HER2-positive GC, other HER2-targeted therapies have not demonstrated survival benefits in patients with GC, despite showing efficacy in patients with HER2-positive breast cancer. This indicates that there are unique challenges to the use of currently available HER2-targeted therapies for the treatment of HER2-positive GC. Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate consisting of an anti-HER2 human monoclonal IgG1 antibody with the same amino acid sequence as trastuzumab, an enzymatically cleavable peptide-based linker, and DXd, a novel topoisomerase I inhibitor, as its released payload. T-DXd has a high drug–antibody ratio (approximately 8) and a demonstrated bystander antitumor effect. It has demonstrated significant efficacy when compared with standard therapies and is approved as third- or later-line treatment for HER2-positive GC in Japan and second- or later-line treatment in the US. T-DXd treatment is associated with gastrointestinal and hematological adverse events, and a risk of interstitial lung disease (ILD), with the ILD risk being higher in Japan than in countries other than Japan. However, most adverse events, including ILD, can be managed with proactive monitoring and T-DXd dose modification, and initiation of adequate treatment. In this review, we summarize the discovery and development of T-DXd and provide guidance for T-DXd safety management, including ILD monitoring, for patients with HER2-positive GC.

• Publisher: Springer Nature B.V
• Subject: Adverse events / Amino acid sequence / Antibodies / Antigens / Antitumor activity / Breast cancer / Cancer therapies / Chemotherapy / Clinical trials / Cytotoxicity / DNA topoisomerase / Drug dosages / Epidermal growth factor / ErbB-2 protein / FDA approval / Gastric cancer / Hybridization / Immunoglobulin G / Immunohistochemistry / Kinases / Lung diseases / Medical research / Metastasis / Monoclonal antibodies / Peptides / Pharmacokinetics / Toxicity / Trastuzumab / Tumors